L. Véronèse

922 total citations
17 papers, 664 citations indexed

About

L. Véronèse is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, L. Véronèse has authored 17 papers receiving a total of 664 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in L. Véronèse's work include Lung Cancer Treatments and Mutations (5 papers), Fibroblast Growth Factor Research (4 papers) and Melanoma and MAPK Pathways (4 papers). L. Véronèse is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Fibroblast Growth Factor Research (4 papers) and Melanoma and MAPK Pathways (4 papers). L. Véronèse collaborates with scholars based in Switzerland, Italy and United States. L. Véronèse's co-authors include Lada Mitchell, N. Eggmann, Christian P. Turtschi, Paul R. Hilfiker, Jeannine D. Rinderknecht, Olivier Michielin, Reinhard Dummer, Simone M. Goldinger, Lea Felderer and C. Le Tourneau and has published in prestigious journals such as Blood, Neurology and Cancer Research.

In The Last Decade

L. Véronèse

17 papers receiving 644 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L. Véronèse Switzerland 10 428 388 280 85 75 17 664
Michael Fluck Germany 11 501 1.2× 379 1.0× 173 0.6× 82 1.0× 34 0.5× 24 770
Lisa Malburg United States 9 405 0.9× 493 1.3× 181 0.6× 47 0.6× 98 1.3× 14 780
Xueqian Gong United States 8 294 0.7× 304 0.8× 214 0.8× 98 1.2× 97 1.3× 16 581
Guorong Yang China 8 611 1.4× 369 1.0× 181 0.6× 104 1.2× 33 0.4× 19 920
B. Markman Australia 8 293 0.7× 469 1.2× 152 0.5× 102 1.2× 88 1.2× 20 688
Bogusława Karaszewska Poland 16 686 1.6× 312 0.8× 437 1.6× 36 0.4× 71 0.9× 28 976
Kerstin Trunzer Switzerland 10 421 1.0× 236 0.6× 270 1.0× 35 0.4× 54 0.7× 16 556
Martina Makrutzki Spain 8 500 1.2× 268 0.7× 285 1.0× 67 0.8× 128 1.7× 14 699
Timothy Larson United States 14 447 1.0× 373 1.0× 271 1.0× 47 0.6× 171 2.3× 30 792
Suresh Anaganti Italy 9 395 0.9× 343 0.9× 169 0.6× 52 0.6× 132 1.8× 10 814

Countries citing papers authored by L. Véronèse

Since Specialization
Citations

This map shows the geographic impact of L. Véronèse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Véronèse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Véronèse more than expected).

Fields of papers citing papers by L. Véronèse

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Véronèse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Véronèse. The network helps show where L. Véronèse may publish in the future.

Co-authorship network of co-authors of L. Véronèse

This figure shows the co-authorship network connecting the top 25 collaborators of L. Véronèse. A scholar is included among the top collaborators of L. Véronèse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Véronèse. L. Véronèse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Spanggaard, Iben, Marc Matrana, Caio Rocha‐Lima, et al.. (2023). Pemigatinib For Previously Treated Central Nervous System Tumors With Activating FGFR Mutations or Translocations: Results From FIGHT-207 (S17.004). Neurology. 100(17_supplement_2). 2 indexed citations
2.
Rodón, Jordi, Silvia Damian, Muhammad Furqan, et al.. (2023). Abstract CT016: Clinical and translational findings of pemigatinib in previously treated solid tumors with activating FGFR1-3 alterations in the FIGHT-207 study. Cancer Research. 83(8_Supplement). CT016–CT016. 11 indexed citations
3.
Vogel, Arndt, Vaibhav Sahai, Antoine Hollebecque, et al.. (2022). P18 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202. Abstracts. A44.1–A44. 1 indexed citations
4.
Ahluwalia, Manmeet S., Enrico Franceschi, L. Véronèse, et al.. (2022). CTNI-39. FIGHT-209: A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF PEMIGATINIB IN PATIENTS WITH PREVIOUSLY TREATED GLIOBLASTOMA OR OTHER PRIMARY CENTRAL NERVOUS SYSTEM TUMORS WITH ACTIVATING FGFR1-3 ALTERATIONS. Neuro-Oncology. 24(Supplement_7). vii80–vii80. 2 indexed citations
5.
6.
Krebs, Matthew, et al.. (2021). Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications. ESMO Open. 6(2). 100072–100072. 15 indexed citations
7.
Westphalen, C. Benedikt, Matthew Krebs, C. Le Tourneau, et al.. (2021). Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. npj Precision Oncology. 5(1). 86–86. 6 indexed citations
8.
Westphalen, C. Benedikt, Matthew Krebs, C. Le Tourneau, et al.. (2021). Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. npj Precision Oncology. 5(1). 69–69. 129 indexed citations
9.
John, Thomas, Marwan Fakih, Anna F. Farago, et al.. (2020). 364O Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases. Annals of Oncology. 31. S397–S398. 9 indexed citations
10.
Liu, Stephen V., Filippo de Braud, Alexander Drilon, et al.. (2020). 540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy. Annals of Oncology. 31. S472–S473. 1 indexed citations
11.
Raje, Noopur, Ian Chau, David M. Hyman, et al.. (2018). Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology. 2(2). 1–9. 22 indexed citations
12.
Bensch, Frederike, Annelies Jorritsma, Marjolijn N. Lub‐de Hooge, et al.. (2017). Abstract CT017: First-in-human PET imaging with the PD-L1 antibody 89Zr-atezolizumab. Cancer Research. 77(13_Supplement). CT017–CT017. 11 indexed citations
13.
Raje, Noopur, Ian Chau, David M. Hyman, et al.. (2015). Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. Blood. 126(23). 4263–4263. 9 indexed citations
14.
Larkin, James, Michele Del Vecchio, Paolo A. Ascierto, et al.. (2014). Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. The Lancet Oncology. 15(4). 436–444. 193 indexed citations
15.
Dummer, Reinhard, Simone M. Goldinger, Christian P. Turtschi, et al.. (2013). Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. European Journal of Cancer. 50(3). 611–621. 230 indexed citations
16.
Dummer, Reinhard, Simone M. Goldinger, Christian P. Turtschi, et al.. (2012). Open-Label Pilot Study of Vemurafenib in Previously Treated Metastatic Melanoma (MM) Patients (PTS) with Symptomatic Brain Metastases (BM). Annals of Oncology. 23. ix366–ix366. 12 indexed citations
17.
Murgia, Marta, Marta Mion, L. Véronèse, et al.. (1994). Cytosolic free calcium concentration in the mitogenic stimulation of T lymphocytes by anti-CD3 monoclonal antibodies. Cell Calcium. 16(3). 167–180. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Fluck Breakdown of academic impact, for papers by Lisa Malburg Breakdown of academic impact, for papers by Xueqian Gong Breakdown of academic impact, for papers by Guorong Yang Breakdown of academic impact, for papers by B. Markman Breakdown of academic impact, for papers by Bogusława Karaszewska Breakdown of academic impact, for papers by Kerstin Trunzer Breakdown of academic impact, for papers by Martina Makrutzki Breakdown of academic impact, for papers by Timothy Larson Breakdown of academic impact, for papers by Suresh Anaganti
Rankless by CCL
2026